Modeling regulatory mechanisms in IL‐6 signal transduction in hepatocytes

  title={Modeling regulatory mechanisms in IL‐6 signal transduction in hepatocytes},
  author={Abhay Kumar Singh and Arul Jayaraman and Juergen Hahn},
  journal={Biotechnology and Bioengineering},
Cytokines like interleukin‐6 (IL‐6) play an important role in triggering the acute phase response of the body to injury or inflammation. Signaling by IL‐6 involves two pathways: Janus‐associated kinases (JAK) and signal transducers and activators of transcription (STAT 3) are activated in the first pathway while the second pathway involves the activation of mitogen‐activated protein kinases (MAPK). While it is recognized that both pathways play a major role in IL‐6 signal transduction, a… 

Inferring relevant control mechanisms for interleukin‐12 signaling in naïve CD4+ T cells

A mathematical model of the canonical IL‐12 signaling pathway used in conjunction with a Bayesian framework provided high‐confidence predictions of the system‐specific control mechanisms from the available experimental observations.

Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling

A crosstalk model of the IFN-gamma and IL-6 pathways was developed that provided a good explanation of the experimental observations and provided insights that may inform further research to facilitate a better understanding of the cross-regulation mechanism between the two pathways.

Investigation of IL-6 and IL-10 signalling via mathematical modelling.

A model was developed which includes interaction between IL-6 and IL-10 signalling as both mechanisms share signal transduction through the Jak-STAT pathway and the activity ratio of Jak- STAT and Erk-C∕EBP was investigated.

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib

Using model simulations coupled with experimental validation, the concept of improved efficacy of the inhibitor through multiple treatments at optimized time intervals was confirmed in primary human hepatocytes and suggests that repetitive treatment with Ruxolitinib is required to effectively target excessive inflammatory responses without exceeding doses recommended by the clinical guidelines.

Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling.

An identifiable model of early Jak/STAT signaling is proposed that describes the data and proves to be predictive and implies that the stepwise association of IL-6 with gp80 and gp130 and STAT3 dimerization at the receptor are essential for the dynamics of early pathway activation.

Systems biology of JAK/STAT signalling.

A data-based model of the core module of the JAK2/STAT5 signalling pathway showed that rapid nucleocytoplasmic cycling of STAT5 is an essential pathway property.

Modeling the Dynamics of Acute Phase Protein Expression in Human Hepatoma Cells Stimulated by IL-6

It was found that gp80, JAK, and gp130 were the three most promising drug targets and that it was possible to reduce the therapeutic dosage by combining drugs aimed at the top three targets in a cocktail.

Dynamic Redox Regulation of IL-4 Signaling

A systems-level model of IL-4 signaling was developed that integrates synchronous pan-PTP oxidation with ROS-independent mechanisms, offers novel hypotheses about regulation of JAK/STAT signaling, and provides a framework for interrogating putative mechanisms involving receptor-initiated oxidation.

Mathematical Modeling of Pro- and Anti-Inflammatory Signaling in Macrophages

A mathematical model to describe integrated pro- and anti-inflammatory signaling in macrophages is developed and represents a first step towards modeling the interaction between pro-and-anti- inflammatory signaling.

Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling

This study contributes to the understanding of molecular mechanisms of IL-6 signal transduction and underlines the power of combined dynamical modelling, model-based validation and biological experiments for future precision medicine approaches that aim to selectively block pro-inflammatory trans-signalling.



SOCS3 regulates the plasticity of gp130 signaling

It is shown that phosphorylation of STAT3 is prolonged in mouse Socs3-deficient macrophages after stimulation with interleukin-6 (IL-6) but not IL-10, indicating that SOCS3 specifically affects signaling mediated by IL-6 and gp130.

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Although all IL-6-type cytokines signal through the gp130/Jak/STAT pathway, the comparison of their physiological properties shows that they elicit not only similar, but also distinct, biological responses.

Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

This review focuses on recent progress in the understanding of the molecular mechanisms of IL-6-type cytokine signal transduction, with emphasis on the termination and modulation of the JAK/STAT signalling pathway mediated by tyrosine phosphatases, the SOCS (suppressor of cytokine signalling) feedback inhibitors and PIAS (protein inhibitor of activated STAT) proteins.

Dual Signaling Role of the Protein Tyrosine Phosphatase SHP-2 in Regulating Expression of Acute-Phase Plasma Proteins by Interleukin-6 Cytokine Receptors in Hepatic Cells

This study shows that in hepatoma cells, the recruitment and tyrosine phosphorylation of SHP-2, but not SHC, is the primary signaling event associated with the activation of MAP kinases (ERK1/2) by gp130, and suggests that IL-6 regulation of APP genes is affected by SHp-2 in two ways.

Control mechanism of JAK/STAT signal transduction pathway

The STAT3-independent Signaling Pathway by Glycoprotein 130 in Hepatic Cells*

Box3-derived and Box3-independent signals cooperate in the control of hepatic APP genes and that Box3 may be involved in the modulation of MAPK activity in gp130 signaling are indicated.

SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130*

Experiments suggest, that there are two, largely distinct modes of negative regulation of gp130 activity, despite the fact that both SOCS3 and SHP2 are recruited to the same site within gp130.

The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling.

Interestingly, in contrast to inhibition, desensitization does not depend on the presence of functional SHP2 and cells lacking SOCS3 show constitutive STAT3 activation which is not affected by pre-stimulation with IL-6, suggesting that desensItization and inhibition of signalling are mechanistically distinct.

SOCS3 Exerts Its Inhibitory Function on Interleukin-6 Signal Transduction through the SHP2 Recruitment Site of gp130*

The interplay of two inhibitors in the signal transduction pathway of interleukin-6 is analyzed and it is demonstrated that the tyrosine phosphatase SHP2 and SOCS3 do not act independently but are functionally linked.

Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.

It is confirmed that frequent hypermethylation of the functional SOCS-3 promoter correlates with its transcription silencing in NSCLC cell lines and primary lung cancer tissue samples and may be useful for the treatment of lung cancer.